



23 December 2016

**IXICO plc  
("IXICO" or the "Company")**

***Buyback and cancellation of Deferred Shares***

IXICO, the brain health company, announces that it has repurchased, for nominal value, and cancelled deferred shares of 49 pence each in the share capital of the Company. The deferred shares were issued as part of a share capital restructuring undertaken in conjunction with the acquisition of Optimal Medicine Group and was announced on 18 November 2015.

**For further information please contact:**

**IXICO plc**

Derek Hill, Chief Executive Officer

Tel: +44 20 3763 7499

Susan Lowther, Chief Financial Officer

**Shore Capital (Nomad and Broker)**

Tel: +44 20 7408 4090

Bidhi Bhoma / Edward Mansfield

**FTI Consulting Limited (Investor Relations)**

Tel: +44 20 3727 1000

Simon Conway/Mo Noonan/Matthew Moss

**About IXICO**

IXICO's innovative and proprietary digital healthcare technologies help those involved in researching and treating serious diseases to capture and analyse clinical data to make rapid, informed decisions. In clinical research this includes the phenotyping of patients, quantification of disease pathology and measurement of patient outcomes. In clinical practice the mobile health and digital decision support technologies aid diagnosis, patient engagement and monitoring. IXICO is also collaborating with partners to develop companion digital health products targeted at improving patient outcomes.

The Company's brain health focus includes Alzheimer's disease, Huntington's disease, multiple sclerosis, Parkinson's disease, behavioural health, child and adolescent mental health.

More information is available on [www.ixico.com](http://www.ixico.com)

**Office:** +44 (0)20 3763 7499 | **Email:** [info@ixico.net](mailto:info@ixico.net)

IXICO plc - Registered in UK no. 03131723 | **VAT Registration No.** 658 1840 14

**Registered Office:** 4<sup>th</sup> Floor, Griffin Court, LONDON EC1A 9PN, United Kingdom